Fatma Arzu Akkuş, Fatih Çölkesen, Tuğba Önalan, Recep Evcen, Filiz Sadi Aykan, Mehmet Kılınç, Mehmet Emin Gerek, Şevket Arslan
{"title":"与奥玛珠单抗治疗慢性自发性荨麻疹疗效相关的因素。","authors":"Fatma Arzu Akkuş, Fatih Çölkesen, Tuğba Önalan, Recep Evcen, Filiz Sadi Aykan, Mehmet Kılınç, Mehmet Emin Gerek, Şevket Arslan","doi":"10.15586/aei.v53i2.1207","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Omalizumab is a preferred treatment in antihistamine-refractory chronic spontaneous urticaria (CSU) patients. However, factors that may impact treatment response remain to be explored.</p><p><strong>Objective: </strong>This study aimed to examine the factors affecting treatment response in CSU patients receiving omalizumab.</p><p><strong>Methods: </strong>This was a retrospective study that included 123 patients who received omalizumab treatment for CSU between January 2015 and April 2024. After administering omalizumab, we evaluated therapeutic efficacy with the urticaria control test (UCT). According to UCT, patients were classified as complete responders, partial responders, and nonresponders.</p><p><strong>Results: </strong>The median age of the patients was 42 (31-50) years, and there were 77 (62.9%) female patients. Sixty-four (52%) patients exhibited complete response, and 43 (35%) patients exhibited partial response to omalizumab treatment, whereas 16 (13%) patients were nonresponders. Autoimmune disease (AID) was present in 31 (25.2%) patients. The most common AID was thyroid autoimmunity, seen in 24 (77.4%) patients. AID was significantly higher in omalizumab treatment nonresponders than in partial and complete responders. The presence of an autoimmune thyroid disease was an independent risk factor for failure to respond to omalizumab treatment. Baseline IgE levels were significantly higher in omalizumab treatment responders with a complete response compared to those with a partial response and nonresponders.</p><p><strong>Conclusion: </strong>Response to omalizumab treatment was influenced by the presence of an AID and baseline serum total IgE level. A concurrent autoimmune thyroid disease was found to be an independent risk factor affecting failed treatment response. Factors that can predict response to omalizumab treatment can help guide patients to more effective treatment.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"1-7"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria.\",\"authors\":\"Fatma Arzu Akkuş, Fatih Çölkesen, Tuğba Önalan, Recep Evcen, Filiz Sadi Aykan, Mehmet Kılınç, Mehmet Emin Gerek, Şevket Arslan\",\"doi\":\"10.15586/aei.v53i2.1207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Omalizumab is a preferred treatment in antihistamine-refractory chronic spontaneous urticaria (CSU) patients. However, factors that may impact treatment response remain to be explored.</p><p><strong>Objective: </strong>This study aimed to examine the factors affecting treatment response in CSU patients receiving omalizumab.</p><p><strong>Methods: </strong>This was a retrospective study that included 123 patients who received omalizumab treatment for CSU between January 2015 and April 2024. After administering omalizumab, we evaluated therapeutic efficacy with the urticaria control test (UCT). According to UCT, patients were classified as complete responders, partial responders, and nonresponders.</p><p><strong>Results: </strong>The median age of the patients was 42 (31-50) years, and there were 77 (62.9%) female patients. Sixty-four (52%) patients exhibited complete response, and 43 (35%) patients exhibited partial response to omalizumab treatment, whereas 16 (13%) patients were nonresponders. Autoimmune disease (AID) was present in 31 (25.2%) patients. The most common AID was thyroid autoimmunity, seen in 24 (77.4%) patients. AID was significantly higher in omalizumab treatment nonresponders than in partial and complete responders. The presence of an autoimmune thyroid disease was an independent risk factor for failure to respond to omalizumab treatment. Baseline IgE levels were significantly higher in omalizumab treatment responders with a complete response compared to those with a partial response and nonresponders.</p><p><strong>Conclusion: </strong>Response to omalizumab treatment was influenced by the presence of an AID and baseline serum total IgE level. A concurrent autoimmune thyroid disease was found to be an independent risk factor affecting failed treatment response. Factors that can predict response to omalizumab treatment can help guide patients to more effective treatment.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"53 2\",\"pages\":\"1-7\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v53i2.1207\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i2.1207","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria.
Background: Omalizumab is a preferred treatment in antihistamine-refractory chronic spontaneous urticaria (CSU) patients. However, factors that may impact treatment response remain to be explored.
Objective: This study aimed to examine the factors affecting treatment response in CSU patients receiving omalizumab.
Methods: This was a retrospective study that included 123 patients who received omalizumab treatment for CSU between January 2015 and April 2024. After administering omalizumab, we evaluated therapeutic efficacy with the urticaria control test (UCT). According to UCT, patients were classified as complete responders, partial responders, and nonresponders.
Results: The median age of the patients was 42 (31-50) years, and there were 77 (62.9%) female patients. Sixty-four (52%) patients exhibited complete response, and 43 (35%) patients exhibited partial response to omalizumab treatment, whereas 16 (13%) patients were nonresponders. Autoimmune disease (AID) was present in 31 (25.2%) patients. The most common AID was thyroid autoimmunity, seen in 24 (77.4%) patients. AID was significantly higher in omalizumab treatment nonresponders than in partial and complete responders. The presence of an autoimmune thyroid disease was an independent risk factor for failure to respond to omalizumab treatment. Baseline IgE levels were significantly higher in omalizumab treatment responders with a complete response compared to those with a partial response and nonresponders.
Conclusion: Response to omalizumab treatment was influenced by the presence of an AID and baseline serum total IgE level. A concurrent autoimmune thyroid disease was found to be an independent risk factor affecting failed treatment response. Factors that can predict response to omalizumab treatment can help guide patients to more effective treatment.
期刊介绍：
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
